Pleconaril - Apodemus
Alternative Names: APO-P001Latest Information Update: 07 Nov 2023
Price :
$50 *
At a glance
- Originator Apodemus
- Class Antidementias; Antivirals; Oxadiazoles; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis; Viral infections
- No development reported Alzheimer's disease
Most Recent Events
- 02 Oct 2023 Pharmacodynamics data from a Phase-II clinical trials in Viral infections presented at the59th Annual Meeting of the European Association for the Study of Diabetes 2023 (EASD-2023)
- 30 Nov 2022 No development reported - Phase-II for Alzheimer's disease (Adjunctive treatment, In the elderly, In adults) in Poland (PO)
- 30 Nov 2022 No development reported- Phase-II for Alzheimer's disease (Adjunctive treatment, In the elderly, In adults) in Czech Republic (PO)